Material Event (Form 8-K)

Item 8.01 Other Events

The Combined 2025 and 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Galera Therapeutics, Inc. (the "Company") has been scheduled for May 8, 2026.

Due to the fact that the date for the Annual Meeting is more than 60 days after the anniversary of the 2024 Annual Meeting of Stockholders of the Company, which was held on February 24, 2025, the Company is providing the new deadline for submission of any qualified stockholder proposal or qualified stockholder nomination.

Stockholders who wish to bring a director nomination or stockholder proposal other than by means of inclusion of a stockholder proposal in the Company's proxy materials pursuant to Rule 14a-8under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), before the Annual Meeting must comply with the requirements set forth in the Company's Amended and Restated Bylaws (the "Bylaws"). The advance notice provisions of the Bylaws contain informational content requirements that must be met when providing notice to the Company of matters to be brought before the Annual Meeting. The Bylaws require that any such stockholder's notice be delivered to, or mailed and received by, the secretary of the Company, Joel Sussman, at the principal executive office of the Company not later than April 13, 2026. The Company's principal executive office is at 101 Lindenwood Drive, Suite 225, Malvern, Pennsylvania 19355.

To comply with the universal proxy rules pursuant to Rule 14a-19under the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees must additionally provide notice to the Company setting forth the information required by Rule 14a-19(b)under the Exchange Act, and such notice must be postmarked or transmitted electronically to the Company at its principal executive office no later than April 13, 2026.

For stockholders who intend to have a proposal considered for inclusion in the Company's proxy materials for the Annual Meeting pursuant to Rule 14a-8under the Exchange Act, such proposal must be received by the Company at its principal executive office no later than a reasonable time before the Company begins to print and send its proxy materials for the Annual Meeting to stockholders. The Company will consider proposals received on or before April 13, 2026 to have been received a reasonable time before the Company begins to print and send its proxy materials.